Sign up for email alert when new content gets added: Sign up
Jun Dou, Mei Guo, Fengshu Zhao, Di Wu, Miao Li, Meng Pan, Jing Wang and Fangfang Shi
Southeast University, China
Posters & Accepted Abstracts: J Microbio and Biotech Rept
Statement of the Problem: Colon cancer is the most common malignant gastrointestinal cancers that are still the most frequent cause of cancer-related mortality in China. Colon Cancer Stem Cells (CCSCs) are the main reasons that result in the drug and radiation resistance, invasive growth, metastasis and cancer relapse. Though many factors involving immuno surveillance and immunosuppression were recently validated as important for patient prognosis, a lot of experimental immunotherapies to fight unresectable metastatic colorectal cancer, only few cases have successfully induced antitumor immune response against malignancies. The aim of this work was to investigate the effects on the inhibition of colon cancer growth by vaccination of CCSC vaccines. Method: The CD133+CSCs were isolated from human LOVO and mouse CT26 cell lines by using a magnetic-activated cell sorting system, respectively. The xenograft or syngeneic mice were subcutaneously inoculated with the LOVO or CT26 CD133+CSC vaccine inactivated with again and again freeze thawing three times before the mice were challenged subcutaneously with LOVO or CT26 cells. The inhibition tumor efficacy was assessed by the tumorigenicity, immune efficient analysis by flow cytometer and enzyme-linked immunosorbent assays, respectively. Result: The results showed that, compared with the non-CSC vaccine, the inhibition tumor growth efficacy of LOVO or CT26 CSC vaccine was significantly increased in the xenograft or syngeneic mice. Vaccination of LOVO or CT26 CD133+CSC vaccine resulted in increasing cytotoxic activity of natural killer cells, enhancing serum IFN-�³ and decreasing TGF- �² levels in the mice. The LOVO and CT26 CD133+CSC vaccines significantly reduced the CSC subpopulations in the colon cancer tissues. Conclusion: The data provided the first evidence that the human LOVO or mouse CT26 CD133+CSC-based vaccine may be an attractive therapeutic approach to excitation of anti-tumor immunity for treatment of colon cancer.
E-mail:
njdoujun@seu.edu.cn
